New prostate cancer vaccine shows promise

There are many health concerns today when it comes to illnesses, but one of the number one health concerns for a man to consider is prostate cancer. There are already treatments available for this type of cancer, but now there is a new one to consider. Provenge, which an experimental treatment vaccine for advanced prostate cancer, has met researchers’ goal in a key trial that is needed to get FDA approval. This news was recently announced by Dendreon, which is the company that makes the vaccine Provenge. Mitchell Gold, M.D. and the president and chief executive of Dendreon, said that they believe that this vaccine is truly a breakthrough for the prostate cancer community a testament to the promise of the field for cancer immunotherapies. Provenge is a biologic drug that is given by infusion to spur the immune system to help fight against advanced prostate cancer that does not respond to anti-androgen treatment. Share and Enjoy:

Childhood vaccines at all-time high, but access not yet equitable

21 OCTOBER 2009 | WASHINGTON, DC | GENEVA – Reversing a downward trend, immunization rates are now at their highest ever and vaccine development worldwide is booming, according to ... Share and Enjoy: